Pharmacokinetics, SAfety/tolerability, and EFficacy of high-dose RIFampicin in tuberculosis-HIV co-infected patients on efavirenz- or dolutegravir-based antiretroviral therapy: study protocol for an open-label, phase II clinical trial (SAEFRIF)

BACKGROUND: Tuberculosis (TB) is a significant public health problem that causes substantial morbidity and mortality. Current first-line anti-TB chemotherapy, although very effective, has limitations including long-treatment duration with a possibility of non-adherence, drug interactions, and toxici...

Descripción completa

Detalles Bibliográficos
Autores principales: Nabisere, Ruth, Musaazi, Joseph, Denti, Paolo, Aber, Florence, Lamorde, Mohammed, Dooley, Kelly E., Aarnoutse, Rob, Sloan, Derek J., Sekaggya-Wiltshire, Christine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7020342/
https://www.ncbi.nlm.nih.gov/pubmed/32054536
http://dx.doi.org/10.1186/s13063-020-4132-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7020342/
https://www.ncbi.nlm.nih.gov/pubmed/32054536
http://dx.doi.org/10.1186/s13063-020-4132-7

Ejemplares similares